Add office photos
Employer?
Claim Account for FREE
Johnson & Johnson
4.0
based on 1.4k Reviews
Video summary
Company Overview
Associated Companies
Company Locations
Working at Johnson & Johnson
Company Summary
Johnson & Johnson operates in the healthcare sector, focusing on innovation to enhance global health outcomes through consumer products and medical solutions.
Overall Rating
4.0/5
based on 1.4k reviews
3% above
industry average
Highly rated for
Company culture, Salary, Work-life balance
Critically rated for
Promotions
Work Policy
Hybrid
54% employees reported
Monday to Saturday
48% employees reported
Flexible timing
69% employees reported
Within city
38% employees reported
View detailed work policy
Top Employees Benefits
Job/Soft skill training
115 employees reported
Health insurance
100 employees reported
Office gym
59 employees reported
Office cab/shuttle
52 employees reported
View all benefits
About Johnson & Johnson
Founded in1957 (68 yrs old)
India Employee Count1k-5k
Global Employee Count1 Lakh+
HeadquartersNew Brunswick, New Jersey, United States (USA)
Office Locations
Websitejnj.in
Primary Industry
Other Industries
Are you managing Johnson & Johnson's employer brand? To edit company information,
claim this page for free
View in video summary
Caring for the world, one person at a time inspires and unites the people of Johnson & Johnson. We embrace innovation—bringing ideas, products, and services to life to advance the health and well-being of people around the world. We believe in collaboration, and that has led to breakthrough after breakthrough, from medical miracles that have changed lives, to the simple consumer products that make every day a little better. Our over 125,000 employees in 60 countries are united in a common mission: to help people everywhere live longer, healthier, happier lives.
Managing your company's employer brand?
Claim this Company Page for FREE
Brands of Johnson & Johnson
Medical Devices
3.9
• 18 reviews
Johnson & Johnson Ratings
based on 1.4k reviews
Overall Rating
4.0/5
How AmbitionBox ratings work?
5
746
4
336
3
138
2
65
1
92
Category Ratings
3.9
Company culture
3.9
Salary
3.9
Work-life balance
3.9
Skill development
3.8
Work satisfaction
3.7
Job security
3.3
Promotions
Johnson & Johnson is rated 4.0 out of 5 stars on AmbitionBox, based on 1.4k company reviews. This rating reflects a generally positive employee experience, indicating satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at Johnson & Johnson
based on 1.3k reviews
3.8
Rated by 228 Women
Rated 3.7 for Work-life balance and 3.7 for Company culture
4.1
Rated by 1k Men
Rated 4.0 for Work-life balance and 4.0 for Company culture
Work Policy at Johnson & Johnson
based on 135 reviews in last 6 months
Hybrid
54%
Work from office
41%
Permanent work from home
5%
Johnson & Johnson Reviews
Top mentions in Johnson & Johnson Reviews
+ 5 more
Compare Johnson & Johnson with Similar Companies
Change Company | Change Company | Change Company | ||
|---|---|---|---|---|
Overall Rating | 4.0/5 based on 1.4k reviews | 4.1/5 based on 1.6k reviews | 4.1/5 based on 1.8k reviews | 4.1/5 based on 1.4k reviews |
Highly Rated for | Skill development Work-life balance Salary | Work-life balance Company culture Salary | Company culture Skill development Work-life balance | Skill development Company culture Work-life balance |
Critically Rated for | Promotions | Promotions | No critically rated category | No critically rated category |
Primary Work Policy | Hybrid 54% employees reported | Hybrid 88% employees reported | Hybrid 70% employees reported | Work from office 57% employees reported |
Rating by Women Employees | 3.8 Good rated by 228 women | 4.1 Good rated by 379 women | 4.1 Good rated by 277 women | 4.2 Good rated by 160 women |
Rating by Men Employees | 4.1 Good rated by 1k men | 4.1 Good rated by 1.1k men | 4.1 Good rated by 1.5k men | 4.1 Good rated by 1.1k men |
Job security | 3.7 Good | 3.8 Good | 3.7 Good | 3.9 Good |
View more
Johnson & Johnson Salaries
Johnson & Johnson salaries have received with an average score of 3.9 out of 5 by 1.4k employees.
District Manager
(119 salaries)
Unlock
₹6 L/yr - ₹13 L/yr
Associate District Manager
(108 salaries)
Unlock
₹4 L/yr - ₹11 L/yr
Medical Representative
(107 salaries)
Unlock
₹1.8 L/yr - ₹6 L/yr
Field Manager
(101 salaries)
Unlock
₹10 L/yr - ₹22.3 L/yr
Area Sales Manager
(85 salaries)
Unlock
₹6.2 L/yr - ₹22 L/yr
Data Analyst
(69 salaries)
Unlock
₹3 L/yr - ₹13 L/yr
Area Business Incharge
(68 salaries)
Unlock
₹7.7 L/yr - ₹17 L/yr
Sales Executive
(66 salaries)
Unlock
₹1.2 L/yr - ₹5 L/yr
Key Account Manager
(66 salaries)
Unlock
₹6.1 L/yr - ₹15.7 L/yr
Medical Sales Representative
(63 salaries)
Unlock
₹2.4 L/yr - ₹6 L/yr
Johnson & Johnson Interview Questions
Interview questions by designation
Top Johnson & Johnson interview questions and answers
Get interview-ready with top interview questions
Johnson & Johnson Jobs
Popular Designations Johnson & Johnson Hires for
Popular Skills Johnson & Johnson Hires for
Current Openings
Johnson & Johnson News
View all
Stock Market Warning: Consumer Confidence Plunged
- The Conference Board’s Consumer Confidence Index reported a significant decline, with a reading of 98.3 compared to 105 in January.
- The average 12-month inflation expectation increased to 6% in February, up from 5.2%.
- Investors are advised to hold consumer defensive stocks, such as Procter & Gamble (PG) and Johnson & Johnson (JNJ) which have been trading near their 52-week highs.
- Stagflation risks are rising as inflation is expected to continue, and the U.S. imposes tariffs on its key trade partners.
Baystreet | 26 Feb, 2025
Will Delta’s $30,000 Compensation Build Long-Term Loyalty or Simply Ease Immediate Crisis?
- Delta Air Lines offered $30,000 compensation to each of the 76 passengers involved in Flight 4819 crash at Toronto Pearson International Airport.
- The response sparked a debate on the effectiveness of compensation in building long-term loyalty and trust.
- Industry experts differ on whether the compensation is a goodwill gesture or a short-term damage control tactic.
- Jason Mudd views Delta's compensation as more of a crisis management strategy than a genuine gesture of goodwill.
- Mudd emphasizes that true customer loyalty is established through consistent actions, not one-time payouts.
- The $30,000 compensation may control the narrative, prevent lawsuits, and make passengers feel heard, but long-term trust requires more than financial settlements.
- Delta loyalists' reactions to the compensation offer will determine its impact on the airline's brand image and customer trust.
- Comparisons are drawn between Delta's response and Johnson & Johnson's renowned crisis management during the Tylenol poisoning incident.
- Experts suggest that for Delta to enhance trust and loyalty, it must focus on safety improvements, transparent communication, and long-term customer care beyond crisis response.
- Customer trust and loyalty play a crucial role in crisis management, where consistent actions are valued over one-time monetary compensations.
Pymnts | 25 Feb, 2025
Union Budget 2025: Cancer medicines and patient assistance programmes come in for reprieve
- Medicines from multinational companies, including Pembrolizumab (MSD Pharma), Lorlatinib (Pfizer), Ribociclib (Novartis), Selumetinib (Astra Zeneca), Teclistamab (Johnson & Johnson), Cetuximab (Merck Specialities), Brentuximab Vedotin (Takeda); Mepolizumab (GSK Pharma), Risdiplam Powder (Roche), Luspatercept (Bristol Myers Squibb) are among the 37 listed to get Basic Customs Duty exemptions, provided they are given free.
- Additionally, the budget proposes to add 13 new patient assistance programs for supplying medicines free of cost to patients.
- 36 lifesaving drugs and medicines will be added to the list of medicines fully exempted from Basic Customs Duty (BCD), and 6 lifesaving medicines will be eligible for concessional customs duty of 5 percent.
- The budget also plans to establish 200 daycare cancer centers in all district hospitals in the next three years.
HinduBusinessLine | 1 Feb, 2025
Why Markets May Continue the Weekly Rally
- Stock markets gained ground last week ahead of the inauguration, with a pullback in 10-year treasury bond yields.
- Housing starts increased, leading to positive reactions from PulteGroup and D.R. Horton stocks.
- Apple stopped its downtrend and saw a slight increase, but analysts remain skeptical about its artificial intelligence solution's appeal.
- Micron Technology and Nvidia both experienced gains, driven by bullish sentiment in the tech sector.
- This week, upcoming earnings reports include Netflix, Johnson & Johnson, and American Express, with JNJ stock needing strong earnings to recover.
Baystreet | 20 Jan, 2025
Johnson & Johnson To Buy Drugmaker Intra-Cellular For $14.6 Billion
- Johnson & Johnson plans to acquire drugmaker Intra-Cellular Therapies for $14.6 billion.
- The deal represents a nearly 40% premium to Intra-Cellular's closing price on Jan. 10.
- This acquisition will provide Johnson & Johnson access to Intra-Cellular's oral drug Caplyta, used for treating schizophrenia and bipolar disorder.
- Johnson & Johnson plans to fund the deal through a combination of cash and debt.
Baystreet | 13 Jan, 2025
US Stock Markets Today: S&P 500, Nasdaq Down 1% As Wall Street Eyes Tepid Close To 2024
- The Wall Street opened on a negative note on Monday, with the broader index, S&P 500, dipping by 1.23% to 5,897.10 points and the tech-heavy Nasdaq Composite falling 1.44% to 19,438.76 points.
- Stocks like Boeing Co. were down 4.66%, Apple Inc. fell 1.77%, and Nike Inc. Cl B dipped 1.75%. Among the companies that fell in early trade were NVIDIA Corp., JPMorgan Chase & Co., and Johnson & Johnson.
- Among the 11 S&P 500 sectoral indices, all were trading lower against the previous day's close. The loss was led by real estate, utilities, energy, healthcare, and consumer staples among the drags.
- As the US market opened, spot gold was lower 0.37% at $2,611.83, and Brent crude oil was trading 0.47% higher at $74.52.
Bloomberg Quint | 30 Dec, 2024
Biocon Sells Syngene’s Shares Worth Rs 686 Crore
- Biocon Ltd. sold Syngene shares worth Rs 686 crore via block deals on the BSE, reducing its stake while maintaining majority ownership at 52.46%.
- The transaction took place in the open market and none of the buyers belong to the promoter, promoter group, or group companies.
- Biocon's subsidiary Biocon Biologics Ltd. received US FDA approval for Yesintek, a biosimilar for Johnson & Johnson's reference product, Stelara.
- For the second quarter of fiscal 2025, Biocon's consolidated net profit fell 84.3% to Rs 27.1 crore compared to the year-ago period.
Bloomberg Quint | 10 Dec, 2024
Oss-based biotech company Citryll bags €85M funding to fight inflammatory diseases: Here’s how
- Dutch biotech company Citryll has secured €85M in a Series B funding round.
- The funding will be used to advance the clinical development of CIT-013, a monoclonal antibody targeting Neutrophil Extracellular Traps (NETs).
- Investors in the funding round include Johnson & Johnson, Forbion, Novartis Venture Fund, and others.
- Citryll's NET-targeting approach has potential applications in various immune-mediated inflammatory diseases.
SiliconCanals | 10 Dec, 2024
Apple named America’s best-run company of 2024
- Apple has been named America's best-run company of 2024, displacing Microsoft at No. 1 in the Management Top 250 ranking.
- The ranking compares companies based on Peter Drucker's principles and five categories: customer satisfaction, innovation, social responsibility, employee engagement and development, and financial strength.
- Apple emerged as the lone all-star in this year's ranking, while Nvidia and Microsoft came close.
- The top 10 companies in the ranking are Apple, Nvidia, Microsoft, Intel, Mastercard, Johnson & Johnson, Procter & Gamble, Alphabet, Adobe, and Philip Morris International.
Macdailynews | 10 Dec, 2024
Biocon Biologics Receives US FDA Nod For Yesintek, A Biosimilar to J&J's Stelara
- Biocon Biologics has received FDA approval for Yesintek, a biosimilar for Johnson & Johnson's Stelara.
- Yesintek, a monoclonal antibody, will treat Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
- This approval will provide affordable access to high-quality biosimilars for millions of patients worldwide.
- Biocon Biologics is set to commercialize Yesintek in the United States by February 22, 2025.
Bloomberg Quint | 1 Dec, 2024
Powered by
Johnson & Johnson Subsidiaries
Janssen Pharmaceuticals
4.2
• 34 reviews
Johnson & Johnson Medical
4.4
• 27 reviews
Johnson & Johnson Surgical Vision
3.2
• 15 reviews
Janssen
3.4
• 12 reviews
Johnson & Johnson Vision Care
3.7
• 11 reviews
Ethicon
4.5
• 8 reviews
Report error
Johnson & Johnson Offices
Compare Johnson & Johnson with
Pfizer
4.0
Merck
4.3
Abbott
4.1
Bayer
4.1
Sanofi
4.2
Gilead Sciences
3.0
Bristol-Myers Squibb
4.0
Paras Hospital
4.4
GeBBS Healthcare Solutions
3.7
UnitedHealth
4.0
Max Healthcare
4.1
Dr Lal PathLabs
4.2
Redcliffe Labs
4.0
Pacific BPO
3.4
Thyrocare Technologies
3.5
Metropolis Healthcare
4.0
Shalby Hospitals
4.1
GE Healthcare
4.0
Baxter International
4.0
Columbia Asia
4.5
Edit your company information by claiming this page
Contribute & help others!
You can choose to be anonymous
Companies Similar to Johnson & Johnson
Procter & Gamble
Beauty & Wellness, Consumer goods, FMCG, Manufacturing, Metals & Mining
4.1
• 1.4k reviews
GlaxoSmithKline Pharmaceuticals
Biotech & Life sciences, Healthcare / Pharma, Manufacturing, Pharma
4.1
• 1.8k reviews
3.0
• 1 reviews
Bristol-Myers Squibb
Biotech & Life sciences, Pharma
4.0
• 133 reviews
Paras Hospital
Healthcare
4.4
• 2.2k reviews
GeBBS Healthcare Solutions
Financial Services, Healthcare
3.7
• 2.7k reviews
Johnson & Johnson FAQs
When was Johnson & Johnson founded?
Johnson & Johnson was founded in 1957. The company has been operating for 68 years primarily in the Healthcare sector.
Where is the Johnson & Johnson headquarters located?
Johnson & Johnson is headquartered in New Brunswick, New Jersey and has an office in Mumbai
How many employees does Johnson & Johnson have in India?
Johnson & Johnson currently has more than 3,000+ employees in India. Sales & Business Development department appears to have the highest employee count in Johnson & Johnson based on the number of reviews submitted on AmbitionBox.
Does Johnson & Johnson have good work-life balance?
Johnson & Johnson has a Work-Life Balance Rating of 3.9 out of 5 based on 1,300+ employee reviews on AmbitionBox. 79% employees rated Johnson & Johnson 4 or above, while 21% employees rated it 3 or below on work-life balance. This indicates that the majority of employees feel a generally balanced work-life experience, with some opportunities for improvement based on the feedback. We encourage you to read Johnson & Johnson work-life balance reviews for more details
Is Johnson & Johnson good for career growth?
Career growth at Johnson & Johnson is rated as moderate, with a promotions and appraisal rating of 3.3. 21% employees rated Johnson & Johnson 3 or below, while 79% employees rated it 4 or above on promotions/appraisal. This rating suggests that while some employees view growth opportunities favorably, there is scope for improvement based on employee feedback. We recommend reading Johnson & Johnson promotions/appraisals reviews for more detailed insights.
What are the pros and cons of working in Johnson & Johnson?
Working at Johnson & Johnson comes with several advantages and disadvantages. It is highly rated for company culture, salary & benefits and skill development. However, it is poorly rated for promotions / appraisal, based on 1,300+ employee reviews on AmbitionBox.
Stay ahead in your career. Get AmbitionBox app
Helping over 1 Crore job seekers every month in choosing their right fit company
75 Lakh+
Reviews
5 Lakh+
Interviews
4 Crore+
Salaries
1 Cr+
Users/Month
Contribute to help millions
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2024 Info Edge (India) Ltd.
Follow us
